Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Hi-Tech Pharmaceuticals, Citing 'a Witch Hunt,' Responds To Government Allegations

Hi-Tech Pharmaceuticals, Inc. (PRNewsFoto/Hi-Tech Pharmaceuticals, Inc.)

News provided by

Hi-Tech Pharmaceuticals, Inc.

Jun 13, 2018, 08:15 ET

Share this article

Share toX

Share this article

Share toX

NORCROSS, Ga., June 13, 2018 /PRNewswire/ -- Hi-Tech Pharmaceuticals responds to the Government "Witch hunt" against it and its efforts to stop it from selling lawful dietary supplements. The Government in its zeal to stop Hi-Tech from selling DMAA, DHEA and other lawful dietary supplements circumvented telling the grand jury the truth about Hi-Tech's dietary testosterone boosters and prohormone products. The Government's current and absurd position in its indictment omits the fact that only trace amounts of the substances may have been found in Hi-Tech products, thereby misleading the grand jury and the public as to the facts upon which the indictment was brought against Hi-Tech. For instance, the evidence indicates that upon learning only trace amounts of the substances were detected, the government exhibited a willful blindness to these circumstances, and then compounded this reckless conduct by affirmatively instructing the FDA laboratory not to quantify those substances. The recently produced laboratory documents produced reveal the Government's dogged determination to indict Hi-Tech no matter what laboratory testing of Hi-Tech's products revealed – or did not reveal. Indeed, the recent production reveals that the Government tested each of the five products in November of 2016 by two different methods (single and double mass spectrometry) and did not detect controlled substances in any of the products.  The government case agent specifically did not want confirmation of just how low the trace levels of these substances were, as evidenced by a telephone call he had with the FDA lab the day before the last and most sensitive round of testing was performed. In this call, the FDA chemist asked him if he wanted quantification testing performed if only trace amounts of scheduled substances were detected, and he said, "no." Simply put, this is not the conduct of a government charge with a good faith belief that a crime actually occurred.

The Government initial testing as stated above showed no steroids were found in Hi-Tech's products, nonetheless they decided to repeat testing the following month using different and/or increasingly sensitive methods. This time, the test results for the products came back with one of the three following results: (1) no controlled substances detected (again); (2) a questionable identification of a controlled substance; or (3) only a trace amount of a controlled substance. Again, not what the Government was looking for from a company it had decided to indict regardless of the facts. So, the Government tested the products yet again in January of 2017 using various methods, this time including triple mass spectrometry, an even more sensitive method. On this last attempt, tests on each of the products detected a trace amount of a controlled substance – even with the Androdiol and Superdrol products, for which all five prior tests resulted in no finding of a controlled substance.  Thus, the various testing methods employed did not all agree on whether a controlled substance was present in any of the products. Notably, only trace levels could be detected by even the most sensitive of methods, and the levels of these substances could be present in amounts as low as 10 billionths of a gram. These trace amounts are so low that the Schedule III substances would not be "biologically active" upon oral administration, or would not have any favorable or harmful effect on the body to include injury to the health of the person consuming the substance.

What the government also failed to inform the grand jury was that the "prohormone" advertised as being in Hi-Tech's products, dehydroepiandrosterone ("DHEA"), is expressly exempted from the definition of "anabolic steroid" by statute. 21 U.S.C. § 802(41)(A) & (C). As to the nature of the products being sold, the fact that only trace amounts of the Schedule III substances were detected (if at all) is critical to whether a company broke the law because the detection of trace amounts of such substances does not indicate that a crime has taken place. First, the law does not concern itself with all technical violations of the Food, Drug, and Cosmetic Act ("FDCA"). As recognized by the Food and Drug Administration ("FDA"), "it is not possible to produce food or food ingredients that are entirely free from contamination by foreign substances or impurities." Poisonous or Deleterious Substances, Food and Drug Admin., 42 Fed. Reg. 190 (Sept. 30, 1977); see also United States v. Articles … Provimi, 425 F.Supp. 228, 229 (D.N.J. 1977) ("Whether an article in interstate commerce is a food or a drug, the court is well aware that no named substance, whatever it may be, can be 'absolutely pure.'") Thus, the long-recognized "de minimis" doctrine in food and drug law mitigates against unjustifiably harsh consequences of an overly literal interpretation of FDA regulations. In United States v. 900 Cases Peaches, 390 F.Supp. 1006, 1010 the Court stated that strict enforcement "would set a standard which 'would ban all processed food from interstate commerce'"). Additionally, the fact that only trace amounts of the substances may have been detected demonstrates not only that Hi-Tech lacked the requisite intent to commit the felonies, but also that no crime was actually committed in this case under 21 U.S.C. §§ 331, 343, and 841.

For instance, in United States v. Chin Chong, 990 F.Supp.2d 320, 322–23 (E.D.N.Y. 2014), the Government argued that "the knowing importation of a single molecule of a controlled substance constitutes a felony offense, emphasizing that the plain language of [the controlled substances import/export statute] contains no minimum-quantity requirement." In response, the Court noted that: Credible studies indicate that as much as 90% of the paper currency in the United States is contaminated with a "detectable amount" of cocaine. These studies are known not just to the courts, law enforcement, and forensic chemists, but to members of the general public. Would a knowledgeable judge with a contaminated $10 bill carried in his wallet on return to the United States from a judicial conference in London be committing a serious drug crime? The government's wooden interpretation of [the controlled substances import/export statute] would dictate that any individual who enters the United States with a modest amount of United States currency has committed a felony drug offense, assuming the traveler is familiar with the contents of her wallet and these well-known facts on contamination referred to above. In this case, if the government had provided the grand jury with the fact that only trace amounts of controlled substances were detected in Hi-Tech's products, the Government would be taking the similarly untenable position that even a trace amount of such a substance is sufficient to charge a company with a crime – a position that would also provide for charges to be filed against every bank, every hemp and poppy seed producer, and likely every processed food manufacturer in the country.

In actuality, neither the law nor the Government (outside of this case) are deaf to the reality that trace amounts of controlled substances are all around us. For example: The Department of Health and Human Services ("HHS") acknowledges that codeine and morphine are present in poppy seeds in an amount sufficient to cause a urine specimen to test positive for those opioids. As explained by HHS, "[e]ating a normal dietary amount of poppy seeds" can lead to a "substantial" concentration of morphine in the urine. Dept. of Health and Human Serv., Medical Review Officer Guidance Manual for Federal Workplace Drug Testing Programs, at 5-6 and 5-8 (2017). If selling poppy seeds was illegal then every coffee shop and bakery would be closed down and their owners would be put in jail. That clearly is not the law. Additionally, various state legislatures have taken steps to ensure the legality of "industrial hemp" from the plant cannabis sativa, defining the term to include parts and varieties of the plant containing a specified amount of the controlled substance tetrahydrocannabinol ("THC"). See, e.g., W. Va. Code § 19-12E-3(2); Ind. Code § 15-15-13-6; M.G.L.A. 128 § 116; see also 7 U.S.C. § 5940.

The newly disclosed evidence shows the government purposefully withheld critical information from the grand jury and augmented this deception by including misleading information about the ingredients in Hi-Tech's products. More specifically, the evidence shows that well before the government presented their case to the grand jury they knew that the laboratory tests performed on Hi-Tech's products allegedly detected only trace amounts of controlled substances and that they intentionally deprived the grand jury of this information.

About Hi-Tech Pharmaceuticals

Hi-Tech Pharmaceuticals (https://www.hitechpharma.com) is a leading Sports Nutrition manufacturer. Hi-Tech Pharmaceuticals is a cGMP certified company that operates out of Four (4) US Production facilities and (2) Warehouses, totally over 600,000 sq. ft. Hi-Tech Pharmaceuticals has impressive capabilities to supply the global demand of sports supplements, vitamins, and pharmaceuticals. On an annual basis, Hi-Tech Pharmaceuticals can manufacture 35 billion tablets and 10 billion capsules. Hi-Tech Pharmaceuticals can also package 500 million bottles, 250 million blister packs, and 150 million pacquettes.

SOURCE Hi-Tech Pharmaceuticals, Inc.

Related Links

https://hitechpharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.